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Insulin-like growth factor binding proteins (IGFBPs)
were characterized in bovine anterior pituitary tissue,
pituitary conditioned media, and serum collected dur-
ing the preovulatory and early luteal phases of the es-
trous cycle. Effects of in vitro treatments of pituitaries
with luteinizing hormone–releasing hormone (LHRH),
estradiol, and progesterone on IGFBP secretion were
also evaluated. Predominant IGFBPs detected in ante-
rior pituitary tissue by immunoprecipitation, ligand blot-
ting, and Northern blotting were IGFBP-5 (29 kDa),
IGFBP-2 (32 kDa), and IGFBP-3 (36 and 39 kDa dou-
blet). Conditioned culture media contained IGFBP-5,
a slightly larger form of IGFBP-2 (33 kDa), the 36- and
39-kDa forms of IGFBP-3, and a more extensively gly-
cosylated form of IGFBP-3 (44 kDa). In serum, IGFBP-5
was not readily detected, and IGFBP-3 (40- and 44-
kDa doublet) and IGFBP-2 (34 kDa) were larger than
in pituitary tissue. Levels of IGFBP-2, -3, and -5 in pitu-
itary tissue decreased during the preovulatory period
and were lowest in the early luteal phase. Treatment
with LHRH increased IGFBP-2 levels in media twofold.
Estradiol or progesterone did not alter IGFBP secre-
tion in vitro. Predominant IGFBPs produced and released
by anterior pituitary tissue were IGFBP-2, -3 and –5. The
activity of IGFBPs fluctuates in the pituitary in asso-
ciation with changes in stage of estrous cycle, impli-
cating IGFBPs as potential regulators of gonadotrope
function.
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Introduction
Previous research implicates the insulin-like growth fac-
tor (IGF) system as having a role in mediating gonadotro-
pin secretion. IGF-1 alters in vitro secretion of gonadotropins
from rat pituitary cells (1–3) and several human pituitary
adenomas (4). However, the bioavailability of IGF-1 to spe-
cific receptors in vivo is subjected to regulation by IGF-
binding proteins (IGFBPs) (5,6). Several IGFBPs, as well
as IGF-I, have been detected in anterior pituitary tissue from
different species (7–14). Potential importance of the IGF
system in regulating pituitary function is provided by obser-
vations that levels of IGF-1 and IGFBPs in anterior pitui-
tary gland tissue were greater than in the hypophyseal stalk-
median eminence, medial basal hypothalamus, preoptic area
of the hypothalamus, and liver (11,12). While concentra-
tions of IGF-1 remained relatively constant in anterior pitu-
itary glands collected at different stages of the estrous cycle,
levels of IGFBPs were correlated with circulating concen-
trations of progesterone (13), and expression of IGFBP-2
in anterior pituitary tissue was increased by estradiol treat-
ment in rats (15) and ewes (14). Therefore, IGFBP activity,
but not IGF-1, appears to fluctuate in the anterior pituitary
gland. These fluctuations appear to be associated with ovar-
ian, and possibly hypothalamic, factors that influence ante-
rior pituitary gland function. In addition, IGFBPs observed
in pituitary tissue differed from those observed in serum
(13), providing evidence that synthesis and/or processing of
IGFBPs occurs in the pituitary. However, a thorough char-
acterization of IGFBPs synthesized and released by bovine
anterior pituitary tissue during specific stages of the estrous
cycle is lacking.
The objectives of the present study were to obtain fur-
ther knowledge concerning the composition of IGFBPs
in the bovine anterior pituitary gland and the potential
for their secretion from this tissue during the preovulatory
and early luteal phase of the estrous cycle. In addition, the
effects of in vitro treatments with luteinizing hormone-
releasing hormone (LHRH), estradiol, and progesterone on
anterior pituitary release of IGFBPs were evaluated to pro-
vide insight into potential mechanisms regulating IGFBP
secretion.
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Results
IGFBPs in Serum, Pituitary Homogenates,
and Conditioned Media from Pituitary Cultures
Representative profiles of IGFBPs detected in serum, pitu-
itary homogenates, and conditioned media from cultured
pituitary slices are shown in the first three lanes of Fig. 1.
The remaining lanes of Fig. 1 depict IGFBP bands immuno-
precipitated from samples treated with antibodies to IGFBP-
5, -2, and -3. Figure 2 provides another example of IGFBPs
detected in anterior pituitary tissue (first lane) and serum
(third lane) and depicts the influence that treatment with N-
Glycosidase F has on the mass of these binding proteins.
In pituitary tissue and conditioned medium, IGFBP-5
was detected by immunoprecipitation as an ~29-kDa pro-
tein. This protein was smaller (p < 0.01) than a faint 30- to
31-kDa band evident in nonimmunoprecipitated serum
samples and was not affected by N-Glycosidase F (cf. lanes
1, 2, and 3 in Fig. 2). The 30- to 31-kDa IGFBP in serum
was not precipitated with any antibodies used.
All three sample types contained an IGFBP that was
precipitated by antibodies against IGFBP-2. However, the
size of IGFBP-2 differed (p < 0.05) among pituitary tissue
(~32 kDa), conditioned medium (~33 kDa), and serum (34
kDa). A 29- to 30-kDa band was also faintly visible in pitu-
itary homogenates and conditioned medium immunopre-
cipitated with the IGFBP-2 antibody, but not in serum.
Because the IGFBP-3 antiserum crossreacted with IGFBP-
2, proteins precipitated by antibodies to IGFBP-2 were also
evident in samples precipitated with the IGFBP-3 anti-
serum. In addition, the IGFBP-3 antiserum precipitated pro-
teins of approx 44, 39–40, and 36 kDa. As summarized in
Fig. 3, the 44-kDa form of IGFBP-3 was not detected in
ligand blots of pituitary homogenates not subjected to
immunoprecipitation (see third lane of Fig. 1, first lane of
Fig. 2) but was detected in all serum samples. The size of
the 39- to 40-kDa IGFBP-3 detected in homogenates and
conditioned medium from pituitaries was smaller (p < 0.01)
than that observed in serum. The 36-kDa form of IGFBP-
3 was detected in pituitary samples, but not serum. Treat-
ment with N-Glycosidase F reduced the mass of IGFBP-3
in pituitary tissue and serum (Fig. 2).
Two additional bands were observed in ligand blots that
were not detected after immunoprecipitation. These bands
were consistent in size with glycosylated (28 kDa) and non-
glycosylated (24 kDa) forms of IGFBP-4 identified in folli-
cular fluid and serum of cattle (18,27). In serum, the 28-kDa
band was reduced in size by deglycosylation (Fig. 2). The
28- and 24-kDa bands were detected in all serum samples.
By contrast, a 27-kDa band (p < 0.01 for size compared
with the 28-kDa in serum) was detected only in 55% of
tissue homogenates and 61% of conditioned medium sam-
ples (Fig. 3). A 24-kDa protein was detected in 33% of con-
ditioned medium samples but was not detected in tissue from
which conditioned medium was generated.
The proportion of total binding activity accounted for by
each IGFBP differed ( p < 0.05) among sample types (Fig.
3). In serum, IGFBP-3 accounted for the majority (58%) of
total IGF binding activity. By contrast, IGFBP-5 accounted
for the largest proportion of IGF binding activity in condi-
tioned medium (46%) and tissue homogenates (57%).
Effects of LHRH, Estradiol, and Progesterone
on In Vitro Secretion of IGFBPs, LH,
and Follicle-Stimulating Hormone
Incubation of pituitary slices with LHRH resulted in a
twofold increase (p < 0.05) in IGFBP-2 binding activity in
Fig. 1. Ligand blot of serum (SER), pituitary-conditioned me-
dium (CM), and pituitary homogenates (PIT). Samples were sub-
jected to no prior treatment (control) or immunoprecipitation with
antibodies against specific IGFBP (as indicated in top line) prior
to loading onto the gel. Control samples were loaded onto the gel
at 1 µL, 2 mL, and 100 µg total protein equivalent for serum,
conditioned medium, and pituitary homogenates, respectively.
Quantities of samples subjected to immunoprecipitation were
5 µL, 2 mL, and 200 µg total protein equivalent for serum, con-
ditioned medium, and pituitary homogenates, respectively. The
resulting immunoprecipitates of each sample were then loaded
onto the gel. The anti-IGFBP-3 antibody used for this procedure
exhibits crossreactivity with IGFBP-2.
Fig. 2. Ligand blot of pituitary homogenates (PIT) and serum
samples that were untreated (−) or treated with N-Glycosidase F
(+) to remove N-linked glycosylations prior to loading on the gel.
The relative mass of IGFBP-3 (top two bands in each untreated
sample) in both samples and the 28-kDa IGFBP-4 in serum (sec-
ond band from bottom of untreated sample) were reduced after
deglycosylation.
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conditioned medium (5.0 ± 0.5 vs 2.7 ± 0.4 arbitrary units).
The IGFBP-2 binding activity in tissue treated with LHRH
(6.4 ± 0.4) was only slightly greater (p < 0.1) than tissue
cultured without hormone treatment (5.5 ± 0.4). Treatment
with LHRH did not influence binding activity of other
IGFBPs in conditioned medium or tissue. Incubation of pitu-
itary tissue with estradiol or progesterone did not influence
IGFBPs in conditioned medium and pituitary homogenates.
Treatment of pituitary tissue with LHRH resulted in
greater (p < 0.01) concentrations of LH (1494 ± 74 ng/mL)
and follicle-stimulating hormone (FSH) (91 ± 5 ng/mL)
released into the conditioned medium than in nontreated
cultures (1071 ± 76 ng of LH/mL; 61 ± 5 ng of FSH/mL).
Release of gonadotropins into culture medium was not in-
fluenced (p > 0.3) by either estradiol or progesterone. Con-
centrations of FSH (pooled mean ± SEM = 32 ± 11 ng/mg)
and LH (680 ± 280 ng/mg) in pituitary slices were not
different (p > 0.15) among treatment groups.
Effects of Time After Prostaglandin F2α on IGFBPs
The IGF binding activity in pituitary tissue collected from
animals slaughtered at different times after prostaglandin
F2α (PGF2α) is summarized in Fig. 4. Binding activity by each
IGFBP decreased as time after PGF2α increased. The
IGFBP-3 (r = 0.50) and IGFBP-5 (r = 0.56) binding activi-
ties in pituitary tissue were associated (p < 0.05) with circu-
lating concentrations of progesterone during the preovula-
tory period (i.e., d 1 and 2 after PGF2α), but this association
was not evident (p > 0.1) when data from all three time
periods were evaluated. Pituitary IGFBP-2 tended (p < 0.08)
to be inversely (r = −0.45) associated with estradiol concen-
trations of follicular fluid during the preovulatory period.
Northern Blot Detection of IGFBP-5 mRNA
To provide additional evidence for pituitary synthesis of
IGFBP-2, -3, and -5, total cellular RNA from representa-
tive pituitary samples from different animals (n ≥ 5) was
subjected to Northern blot analysis (Fig. 5). A 1.4-kb tran-
script was detected for IGFBP-2 and a 2.4-kb transcript for
IGFBP-3. Transcripts of 6 and 1.8 kb were detected for
IGFBP-5 mRNA.
Discussion
The present study provides evidence that IGFBP-2, -3,
and -5 are synthesized and secreted by bovine anterior pitu-
Fig. 3. Relative percentage of the total IGF-1 binding activity accounted for by individual IGFBPs detected in serum,
conditioned medium, and pituitary slice homogenate samples from 18 animals. Numbers in parentheses represent the
proportion of samples exhibiting binding in that area; no number denotes that samples from all 18 animals exhibited
binding. Identification of proteins is based on immunoblot analysis (Fig. 1). A question mark indicates that identity
of the 29- to 31-kDa protein in serum was not established. The percentage of total binding activity accounted for by
the individual IGFBPs varied (p < 0.05) among the three types of samples.
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itary tissue. Levels of IGFBP activity in the anterior pitu-
itary gland declined from the preovulatory through the early
postovulatory period, and LHRH stimulated pituitary release
of IGFBP-2 in vitro. These results provide additional basis
for the hypothesis that IGFBPs may have an important role
in controlling reproductive function by mediating IGF-1 in-
fluences on gonadotrope function.
The IGFBPs observed in pituitary tissue differed from
those in serum in apparent molecular weight (IGFBP-2 and
-3) and relative abundance. During the physiologic states
evaluated, IGFBP-5 accounted for the majority of total
IGF-1 binding activity in bovine anterior pituitary tissue.
The remainder of the binding activity was primarily owing
to IGFBP-3 and -2, with some samples exhibiting binding
by a protein similar in size to IGFBP-4. In contrast to pitu-
itary samples, very little IGFBP-5 was detected in serum
as reported previously in cattle (18) and other species (5);
IGFBP-3 accounted for the majority of total binding activ-
ity detected in serum of cattle with binding by IGFBP-2
and -4 ranking second and third, respectively; the apparent
sizes of IGFBP-2 and -3 were larger in serum than in ante-
rior pituitary tissue; and serum contained a 30- to 31-kDa
protein that was not detected in pituitary samples. Previous
research indicates that this 30- to 31-kDa protein may be
IGFBP-1 (19), but an antibody to characterize this protein
in cattle was not available.
The proportionately large amount of IGFBP-5 activity
and smaller forms of IGFBP-2 and -3 detected in pituitary
tissue, as compared to serum, are consistent with intrapitu-
itary synthesis and processing of IGFBPs. Detection of
transcripts for IGFBP-2, -3, and -5 provides additional evi-
dence that synthesis of these IGFBPs occurs in pituitary tis-
sue. Transcripts for IGFBP-2, -3, -4, and -5, but not IGFBP-1,
were detected in rat anterior pituitary tissue (9) and IGFBP-
2 mRNA, and protein was detected in ovine pituitary tissue
(14). Rodent pituitaries secrete IGFBPs (7,8,10); however,
the cited studies did not determine whether tissue and secre-
ted forms of IGFBPs differed in size, as was evident for
IGFBP-2 and -3 in the present study. Research in sheep
demonstrated that forms of IGFBP-2 and -3 in pituitary and
stalk medium eminence tissue were smaller than those in
serum (12,14,20), but these studies did not evaluate secre-
tion of IGFBPs. Three potential N-linked glycosylation
sites exist on IGFBP-3 (5), and the present study demon-
strated that pituitary conditioned medium and serum have
an increased predominance of more extensively glycosy-
lated forms of IGFBP-3 than pituitary tissue. Reasons for
differences in relative size of IGFBP-2 in pituitary tissue,
conditioned medium, and serum are not evident but may
not be owing to glycosylation because bovine IGFBP-2
was not predicted to contain O- or N-linked glycosylation
sites (21). Therefore, other posttranslational modifications
of IGFBP-2 may account for differences among these three
sample types. Nevertheless, these studies provide evidence
that IGFBP-2, -3, and -5 are synthesized and processed in
bovine pituitary tissue.
Fig. 4. Activity of IGFBP in pituitary tissue from eight cows
slaughtered at either 1, 2, or 8 to 9 d after PGF2α (PG) to provide
pituitary tissue from preovulatory (1 or 2 d after PGF2α) or early
luteal (8 or 9 d after PGF2α) phases of the estrous cycle. The
p values for each pairwise comparison of mean IGF-binding
activity are given below the graph.
Fig. 5. Representative lanes from Northern blots of 15 µg total
RNA isolated from anterior pituitaries. Blots were probed with
cRNAs for IGFBP-2, -3, and -5 as indicated above each lane.
Location of the 18S ribosomal RNA is indicated on the left. A
single transcript of ~1.4 kb was detected for IGFBP-2. A tran-
script of ~2.4 kb was detected for IGFBP-3. Transcripts for
IGFBP-5 were detected at approx 6 kb and in close proximity to
the 18S ribosomal RNA (~1.8 kb).
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The fact that pituitary tissue contains smaller forms of
IGFBP-2 and -3 than serum emphasizes the need to charac-
terize these proteins by means other than size alone. Interes-
tingly, the size of these proteins observed in bovine uterine
tissue (19) and ovarian follicular cells (16) was not differ-
ent from serum. Therefore, tissue-specific differences in syn-
thesis, storage, and processing may exist.
Mechanisms regulating the synthesis and secretion of
IGFBPs in the anterior pituitary gland remain to be estab-
lished. Short-term treatment of cultured pituitary tissue with
LHRH increased secretion of IGFBP-2 as well as FSH and
LH. To our knowledge, this is the first report demonstrating
that LHRH stimulates pituitary secretion of IGFBPs, and a
role of IGFBPs in mediating hypothalamic control of pitu-
itary function is suggested. Whether this effect will be evi-
dent in situ remains to be established. In contrast to LHRH,
short-term treatment of cultured pituitary tissue with estra-
diol or progesterone did not influence secretion of IGFBPs
or gonadotropins. Because of the short duration of treat-
ments, conclusions regarding the effects, or lack thereof,
of these hormones are limited to influences on secretion.
Longer-term (≥2 wk) in vivo treatment of ovariectomized
animals with estradiol increased pituitary binding activity
and mRNA for IGFBP-2 in rats (15) and ewes (14). In pre-
pubertal cattle, ovariectomy resulted in a significant decrease
in pituitary levels of IGFBP-2, -3, and -5 (unpublished ob-
servation). However, treatment of ovariectomized animals
with estradiol prevented decreases in levels of IGFBP-2 and
IGFBP-5, but not IGFBP-3. Estradiol treatment of ovariec-
tomized ewes also increased IGFBP-2, -3, and -5 in the
stalk median eminence (14), another example of steroid
regulation of IGFBPs in the hypothalamic-pituitary axis.
A limitation of in vitro experiments and studies utiliz-
ing ovariectomized animals is that these experimental ap-
proaches do not account for the total endocrine milieu and
the complex interactions among different hormones that
exist in an intact animal. Observations that IGFBP activity
decreased from d 1 to d 2 after PGF2α (i.e., preovulatory
period) and were even lower 8 to 9 d after PGF2α (i.e., early
luteal phase) provide insight that the interaction among
ovarian and hypothalamic hormones may by important in
regulating IGFBP activity in the anterior pituitary gland.
During the preovulatory period, increased estradiol and
LHRH stimulation of the pituitary would be expected. How-
ever, IGFBP in the tissue decreased during this period.
Thus, factors other than estradiol and LHRH are also likely
to regulate IGFBP activity. Levels of IGFBP-3 and -5 in the
pituitary were associated with decreases in circulating con-
centrations of progesterone whereas IGFBP-2 levels tended
to be inversely associated with estradiol concentration in
the ovulatory follicle. Positive correlations among IGFBP-
2, -3, and -5 in the pituitary and circulating concentrations
of progesterone during the estrous cycle were observed pre-
viously (13). Based on observations of IGFBPs in the intact
animals and results from the in vitro experiment and stud-
ies utilizing ovariectomized animals, it appears that IGFBP
activity in anterior pituitary tissue is regulated by interac-
tions among endocrine input from the hypothalamus and
gonad and is dependent on the balance of effects on synthe-
sis and secretion.
While the physiologic significance of these observations
remains to be confirmed, actions that IGFBPs have in alter-
ing numerous other biologic processes have been studied
in a wide variety of experimental models (see refs. 5 and 6
for review). Depending on the experimental system and
conditions used, IGFBPs can either inhibit or potentiate the
actions of IGFs. Inhibition of these actions is attributed to
the high affinity that IGFBPs bind IGFs, thereby prevent-
ing IGFs from interacting with IGF receptors. Potentiation
of IGF actions involves interaction of individual binding
proteins (i.e., IGFBP-1, -3, and -5) with the cell surface,
thereby increasing the bioavailability of IGFs in the micro-
environment surrounding cells and enhancing ligand-recep-
tor association. In some cases, the ability of IGFBP to poten-
tiate IGF actions is influenced by the phosphorylated state
of the binding protein (IGFBP-1) or proteolytic cleavage of
the IGFBP, which decreases affinity for IGFs. Because bind-
ing affinities for IGF-1 and IGF-2 differ among individual
IGFBPs, the composition of IGFBPs or the posttransla-
tional processing of IGFBPs in anterior pituitary tissue may
markedly influence the interaction of IGFs with IGF recep-
tors on cells in the anterior pituitary. Early research demon-
strated that titration curves of IGF binding in conditioned
medium from rat pituitary tissue were not always parallel
to those observed for serum (7), indicating that the equilib-
rium among IGFs and IGFBPs in the anterior pituitary dif-
fered from that existing in the circulation. Therefore, the
amounts and types of IGFBPs synthesized and processed
within a given tissue or cell type regulates tissue respon-
siveness to the IGFs. In addition to modulating the bio-
availability of IGFs, IGFBP-1, -2, -3, and -5 may also alter
cellular function in an IGF-independent fashion through
interaction with intergrin receptors (IGFBP-1) or other cell
surface binding sites (IGFBP-3 and -5) (see refs. 5 and 6 for
reviews).
It is well established that LHRH and gonadal steroids
interact to regulate synthesis and secretion of gonadotro-
pins. Likewise, LHRH and ovarian steroids also appear to
interact in regulating pituitary levels of IGFBPs. Present
and previous research (13) indicate an inverse relationship
among activities of individual IGFBPs in the pituitary and
circulating concentrations of LH throughout the estrous
cycle. Because IGF-1 can enhance LHRH-stimulated secre-
tion of gonadotropin from pituitary cells (1–4), the inverse
associations of pituitary IGFBPs with circulating concen-
trations of LH are consistent with an inhibitory role of IGFBPs
on IGF-1-stimulated gonadotropin secretion. These obser-
vations provide a basis for the hypothesis that IGFBPs act
within the anterior pituitary to mediate endocrine feedback
loops controlling gonadotrope function. Steroid inhibition
IGFBPs in the Anterior Pituitary / Roberts et al.404 Endocrine
of LH secretion may be mediated, at least in part, by increases
in levels of IGFBP-2, -3, and -5 in the pituitary, which, in
turn, suppress IGF-1 augmentation of LH secretion. The ef-
fects that estradiol and progesterone have on IGFBPs may
be direct or indirect as documented for steroid effects on
pituitary gonadotrope function. While the implications of
LHRH-stimulated release of IGFBP-2 remain to be deter-
mined, increases in IGFBP-2 release may be involved in
the sequestering of IGF-1 and thereby the culmination of
each LH pulse in response to LHRH.
Collectively, the present and discussed studies support
the hypothesis that IGFBPs act within the pituitary to mod-
ulate hypothalamic and ovarian endocrine inputs regulat-
ing reproductive function. However, additional research will
be required to substantiate this hypothetical model.
Materials and Methods
Collection and Processing of Pituitary Tissue
Mature cycling beef cows with a corpus luteum present
on their ovaries were injected with (PGF2α) (Lutalyse;
Upjohn, Kalamazoo, MI) to induce luteolysis. Cows were
then slaughtered at 1 (n = 8), 2 (n = 8), or 8 to 9 (n = 8) d
after injection to provide animals in the preovulatory (d 1
and 2) and early luteal (d 8 and 9) stages of the estrous
cycle. These time points were selected to characterize more
precisely the decline in IGFBP activity previously (13)
reported for cows classified as preovulatory (d 17–21) or
postovulatory (d 1–5).
Blood samples were collected from each animal immedi-
ately after slaughter, and stored overnight at 4°C, and serum
was harvested and stored at −20°C for analysis. Anterior
pituitary glands and ovaries were collected within 20–30
min after exsanguination at slaughter. Trimmed anterior
pituitary glands were either prepared for culture or snap-
frozen in liquid nitrogen. Ovaries were collected for deter-
mination of follicular fluid concentrations of estradiol in
large follicles (all follicles >8 mm diameter) and corpus
luteum weights to verify stage of estrous cycle at slaughter.
Anterior pituitary glands from 15 cows (n = 5/PGF2α
group) were subjected to in vitro culture. Four midsagittal
slices, 1 to 2 mm thick, from each gland were placed in
sterile Petri dishes containing 3 mL of a 1:1 mixture of Dul-
becco’s modified Eagle’s medium:Ham’s F12 (DMEM/F12)
(Gibco-BRL, Gaithersburg, MD). Medium was changed
four times at 45-min intervals to wash the slices. Pituitary
slices were then placed into six-well culture plates contain-
ing 3 mL of DMEM/F12 per well. Tissue slices were incu-
bated for three 40-min intervals under 95% air, 5% CO2 at
37°C. Culture medium was collected after each 40-min
period and replaced with new medium. Medium from the
first two 40-min culture periods was used to determine
baseline levels of IGFBP production. Medium used for the
last 40-min period contained either no hormone (control),
LHRH (66 ng/mL) (Sigma, St. Louis, MO), estradiol (E2)
60 pg/mL), or progesterone (P4) (10 ng/mL). These hor-
mone concentrations were previously shown to influence
LH secretion in cultured bovine pituitary cells (22). Treat-
ments during the last 40 min were randomly applied to one
of the four slices from each animal. After culture, condi-
tioned media were centrifuged and frozen. Pituitary slices
were blotted dry, weighed, snap-frozen in liquid nitrogen,
and stored at -70°C for subsequent analysis of IGFBPs and
concentrations of LH and FSH.
Analysis of Hormones and IGFBPs
Concentrations of LH (23) and FSH (24) in medium and
homogenates of cultured pituitary tissue were determined
by radioimmunoassay. All samples were analyzed in one
assay for each hormone with a coefficient of variation (CV)
of 6 and 8% for LH and FSH, respectively. Sensitivities
(>5% displacement) of each assay were 0.2 ng/tube. Con-
centrations of estradiol in follicular fluid samples and prog-
esterone in serum were determined as described previously
(16), except that progesterone was extracted from serum
with heptane (17) prior to being assayed. All samples were
analyzed in one assay for estradiol or progesterone (CV =
8 and 10%, respectively) with a sensitivity (>5% displace-
ment) of 0.2 and 5 pg/tube, respectively.
Ligand blot procedures (25) were used as described (19)
to evaluate IGFBPs in serum, conditioned medium from
pituitary cultures, and tissue homogenates subjected to
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) (26). Serum samples and a pool of bovine
follicular fluid (used as a positive control on each gel) were
analyzed at a volume of 1 µL of sample diluted in 49 µL of
gel-loading buffer (62.5 mM Tris base; 2% SDS; 0.02%
bromophenol blue; 10% glycerol; pH 6.8). IGFBPs in 1 mL
of conditioned medium from each incubation were concen-
trated by precipitation with 2 vol of ethanol and centrifu-
gation at 12,000g for 15 min. Resulting pellets were resus-
pended in 50 µL of gel-loading buffer and loaded onto the
gels. Pituitary tissue was homogenized at 100 mg of tissue/
mL of buffer (0.1% SDS, 1% cholic acid, 0.1 mM phenyl-
methylsulfonyl fluoride). Total protein concentration in pitu-
itary homogenates was determined by the BCA procedure
(Pierce, Rockford, IL), and samples were diluted with gel-
loading buffer to equivalent quantities of total protein (100
µg) in a total volume of 50 µL. All samples were boiled
4 min and placed on ice for 5–10 min prior to loading into
wells of a 4% stacking gel layered over a 12% separating
gel. Proteins were electrophoretically transferred from the
gel onto nitrocellulose membranes. IGFBPs were detected
by probing with IGF-1 (DRG010; Bachem, Torrance, CA)
radiolabeled with 125I. Preliminary studies indicated that
probing membranes with a mixture of radiolabeled IGF-1
and IGF-2 did not reveal any additional IGFBPs, as those
detected with IGF-1 alone. Autoradiographic film was ex-
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posed to membranes. Band intensity and relative migration
distance of individual binding proteins were determined by
scanning laser densitometry. For the in vitro experiment,
17 samples were generated for each cow: 1 serum, 12 con-
ditioned medium (3 collections for each of four treatments),
and 4 pituitary homogenates (1 for each treatment). The gel
and transfer apparatuses used were capable of running a
total of 48 samples in one set of gels (n ≤ 4) at one time.
Seven sets of gels were run to allow comparisons of in vitro
treatments on IGFBP in media and pituitary homogenates.
Serum samples were also included in this group of gels to
allow comparison of IGFBPs among the different types of
samples. All samples from one animal were included within
a set of gels so that the aforementioned comparisons could
be made on a within-cow basis. An additional set of gels
was run on pituitary homogenates to allow analysis of the
effects of time after PGF2α on IGFBPs.
Identification of IGFBPs in serum (5 µL), anterior pitui-
tary homogenates (200 µg of protein), and conditioned me-
dium (2 mL precipitated with 2 vol of ethanol) was deter-
mined by immunoprecipitation and subsequent ligand blot
analysis (18,27). Samples were immunoprecipitated using
a partially purified (1 mg of IgG/mL) rabbit antirat IGFBP-
2 antibody (28), rabbit antibovine IGFBP-3 antiserum (RK53,
provided by Dr. D. Clemmons, University of North Caro-
lina, Chapel Hill), or rabbit antihuman IGFBP-5 antiserum
(Upstate Biotechnology, Lake Placid, NY). Samples were
incubated overnight at 4°C with 2 µL of antibody solution
or antiserum after which preprecipitated goat antirabbit IgG
antibody suspension was added (27). Samples were subse-
quently centrifuged at 12,000g for 15 min. Precipitates were
resuspended in gel-loading buffer and subjected to SDS-
PAGE and ligand blot procedures.
Deglycosylation of IGFBPs
Serum (1 µL) and pituitary homogenates (25 µg of pro-
tein equivalent) were subjected to N-linked deglycosyla-
tion (27) to provide information on differences in sizes of
IGFBPs. Briefly, samples were incubated overnight at 37°C
in the presence or absence of 0.4 U of recombinant N-Gly-
cosidase F (Boehringer Mannheim) in 20–25 µL of diges-
tion buffer (0.6% Triton X-100; 0.25 M NaPO4, 10 mM
EDTA, pH 7.5). Samples were then mixed with equivalent
volumes of gel-loading buffer and subjected to SDS-PAGE
and ligand blot analysis as already described.
Northern Blot Analysis
Isolation and Northern blot analysis of total RNA were
performed as previously reported (19). In brief, anterior
pituitary gland tissue was homogenized in guanidinium thio-
cyanate, and total RNA was purified through a CsCl gradi-
ent. Samples (15 µg of total RNA; minimum of five samples
for each IGFBP) were denatured, separated by electrophor-
esis through an agarose-formaldehyde gel, and transferred
to a nylon membrane. IGFBP-5 mRNA was then detected
by hybridization with a (32P)-UTP-labeled cRNA antisense
probe transcribed from cDNA templates for rat IGFBP-2
and IGFBP-5 (29) or bovine IGFBP-3 (19).
Statistical Analyses
All data were analyzed by analysis of variance using SAS
general linear models procedures (30). When a fixed effect
was significant (p < 0.05), least squares means for response
variables were compared across groups by the SAS least sig-
nificant differences procedure. Differences among IGFBP
profiles observed in serum, pituitary homogenates, and con-
ditioned medium from pituitary cultures were evaluated
using a randomized block design with cow as the blocking
factor and sample type as a fixed effect. Response variables
analyzed were migration rates of proteins (i.e., location of
bands on gels as determined by scanning densitometry) and
percentage of total IGF binding activity accounted for by
individual IGFBPs.
The effects of in vitro treatment on IGFBP activity and
concentrations of LH and FSH in conditioned medium and
pituitary homogenates were evaluated by a model that in-
cluded cow as a blocking factor and treatment as a fixed
effect. Prior to analysis, data for IGFBPs and gonadotropin
concentration in conditioned medium were divided by
values obtained during the second 40-min incubation (con-
ducted without hormone treatment) to adjust for unequal
secretion rates owing to differences between tissue slices.
The effects of time after PGF2α on IGFBP in pituitary
homogenates were evaluated using gel (n = 2) as the block-
ing factor and day after PGF2α as a fixed effect. The effects
of time after PGF2α on CL weight, circulating levels of prog-
esterone, and concentrations of estradiol in the dominant
follicle were evaluated using a completely random design.
Simple correlations of IGFBP activities in pituitary tissue
with luteal weight, circulating progesterone, and follicular
fluid estradiol concentrations were obtained using the SAS
program (30).
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